PharmaCyte Biotech, Inc.
Data quality: 100%
PMCB
Nasdaq
Manufacturing
Chemicals
$0.68
▲
$0.00
(0.31%)
Mkt Cap: 7.34 M
Price
$0.68
Mkt Cap
7.34 M
Day Range
$0.67 — $0.72
52-Week Range
$0.63 — $1.51
Volume
69,145
Open $0.72
50D / 200D Avg
$0.73
6.82% below
50D / 200D Avg
$0.89
23.46% below
Quick Summary
Key Takeaways
Earnings grew 9084.98% over the past year
Negative free cash flow of -4.80 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)9084.98%
FCF Growth (3Y)N/A
Quality
Return on Equity
-8.95%
Above sector avg (-53.41%)
ROIC-7.83%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio12.33
Interest CoverageN/A
Valuation
PE (TTM)
-2.24
Below sector avg (-1.48)
P/B Ratio0.19
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -2.2 | -1.5 |
| P/B | 0.2 | 1.6 |
| ROE % | -9.0 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | 9084.98% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0.0 | Net Income (TTM) | -3.28 M |
| ROE | -8.95% | ROA | -5.87% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -4.80 M |
| ROIC | -7.83% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 12.33 |
| Interest Coverage | N/A | Asset Turnover | 0.00 |
| Working Capital | 19.02 M | Tangible Book Value | 36.56 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -2.24 | Forward P/E | N/A |
| P/B Ratio | 0.19 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -65.43% | ||
| Market Cap | 7.34 M | Enterprise Value | -12.83 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.89 | Revenue / Share | 0.00 |
| FCF / Share | -0.45 | OCF / Share | -0.45 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 146.29% |
| SBC-Adj. FCF | -5.77 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | 30.66 M | 333,763.0 | -4.32 M | -4.24 M | -3.55 M |
| EPS (Diluted) | 3.19 | -1.80 | -0.22 | -0.27 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -4.38 M | -8.52 M | -6.46 M | -4.39 M | -3.62 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 438,416.0 | 407,431.0 | 468,536.0 | 690,937.0 | 916,249.0 |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | 0.0 | 509.0 | 3,046.0 |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 55.17 M | 59.90 M | 73.28 M | 90.62 M | 7.40 M |
| Total Liabilities | 3.28 M | 20.39 M | 586,581.0 | 704,370.0 | 724,778.0 |
| Shareholders' Equity | 51.89 M | 27.65 M | 72.69 M | 89.92 M | 6.68 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 15.17 M | 50.18 M | 68.04 M | — | — |
| Current Assets | 22.38 M | 50.44 M | 68.15 M | 85.49 M | 2.28 M |
| Current Liabilities | 2.91 M | 7.42 M | 586,581.0 | 704,370.0 | 724,778.0 |
{"event":"ticker_viewed","properties":{"ticker":"PMCB","listing_kind":"stock","pathname":"/stocks/pmcb","exchange":"Nasdaq","country":"US"}}